uniQure CEO Daniel Soland resigns
Mr. Soland served as the new Chief Executive Officer from December 2015. He has more than 30 years of industry experience, most recently serving as Vice President and Chief Operating Officer of ViroPharma.
At ViroPharma, he was responsible for building the company’s organization and commercial infrastructure until its successful sale to Shire in 2014.
Mr. Soland was previously President of Chiron Vaccines, where he helped engineer a turnaround that contributed to Chiron’s acquisition by Novartis.
Earlier, he was President and CEO of Epigenesis Pharmaceuticals and Vice President and Director of Worldwide Marketing Operations at GlaxoSmithKline Biologicals and held positions of increasing responsibility at Pasteur-Merieux’s Connaught Laboratories (now Sanofi Pasteur).
He holds a B.S. in Pharmacy from the University of Iowa.
uniQure appointed Dan Soland as chief executive officer.
Mr. Kapusta joined uniQure as CFO in January 2015 with nearly 20 years of experience in the life sciences industry. Most recently, he was Senior Vice President at AngioDynamics responsible for corporate development, strategic planning and national accounts.
Prior to AngioDynamics, Mr. Kapusta served as Vice President, Finance for Smith & Nephew Orthopaedics. His career also includes more than a decade of investment banking experience focused on emerging life sciences companies.
Mr. Kapusta was Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens and PaineWebber.
Mr. Kapusta holds a Master of Business Administration from New York University's Stern School of Business, a Bachelor of Business Administration from University of Michigan's Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young. ■